The Estée Lauder Companies Collaborate with Serpin Pharma, Inc to Innovate Skin Care Ingredients for Enhanced Longevity

Summary

The Estée Lauder Companies Inc. (ELC) has announced a partnership with Serpin Pharma to apply advanced anti-inflammatory biotechnology to skincare products.

Key Points:

• Objective: The collaboration aims to incorporate Serpin Pharma’s anti-inflammatory research into ELC’s skincare products. This research focuses on enhancing cell resilience and reducing skin irritation, aging, and sensitivity.

• Technology: Serpin Pharma has developed a potent peptide therapeutic to mitigate inflammation, tapping into innate immune responses using SERPIN proteins. This technology shows powerful potential for skincare applications.

• Goals: ELC’s R&D ambitions focus on transformative innovation using groundbreaking scientific discovery across interdisciplinary fields. This partnership is part of ELC’s strategic vision, Beauty Reimagined, which seeks fast-to-market innovation.

• Background: ELC has a reputation in longevity science and biotech, aiming to deliver high-quality skincare by collaborating with leading biotech firms.

• Statements:

  • Carl Haney of ELC emphasized the exploration of new biotech ingredients to reduce skin irritation.
  • Cohava Gelber of Serpin Pharma noted the unique approach of employing the body’s innate mechanisms for resolving inflammation.
• Company Info:
  • ELC: A global leader in prestige beauty, offering a broad range of products sold in 150 countries under various luxury brands.
  • Serpin Pharma: Based in Virginia, specializes in anti-inflammatory therapies, with significant efficacy over natural compounds and a robust patent portfolio.

This collaboration reflects a significant move towards integrating advanced biotechnological insights into consumer skincare, enhancing ELC’s product innovation and market leadership.